Abstract

BackgroundBCMA-targeted chimeric antigen receptor (CAR)T-cell therapy promotes transient recovery in patients with multiple myeloma, but relapses occurs commonly. GPRC5D, a surface receptor that is highly expressed in bone marrow samples...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call